Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.54 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | FPR3 | P25089 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087666 | 0.89 | KDM4E (0.70) | KDM4EPKMTGFBR1BRD4GPR119 | |
| SCHEMBL7090271 | 0.85 | KDM4E (0.71) | KDM4EPKMTGFBR1BRD4GPR119 | |
| SCHEMBL5868022 | 0.84 | GPR119 (0.56) | KDM4EPKMTGFBR1GPR119STS | |
| SCHEMBL7090242 | 0.83 | KDM4E (0.69) | KDM4EPKMTGFBR1BRD4GPR119 | |
| SCHEMBL3040666 | 0.83 | KDM4E (0.62) | KDM4EPKMGPR119STS | |
| SCHEMBL26131403 | 0.82 | KDM4E (1.00) | KDM4EPKMTGFBR1BRD4GPR119 | |
| SCHEMBL6148210 | 0.81 | KDM4E (0.71) | KDM4EPKMTGFBR1BRD4GPR119 | |
| SCHEMBL13930857 | 0.80 | KDM4E (0.61) | KDM4EPKMTGFBR1BRD4GPR119 | |
| SCHEMBL4844156 | 0.79 | GPR119 (0.55) | KDM4EPKMTGFBR1GPR119STS | |
| SCHEMBL4838884 | 0.79 | KDM4E (0.54) | KDM4EPKMTGFBR1GPR119LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1192132-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | KDM4E 2936/4885PKM 1204/4885TGFBR1 2185/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | KDM4E 3503/4885PKM 2089/4885TGFBR1 2222/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | KDM4E 712/4885PKM 1905/4885TGFBR1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.